Evaluation of Fluid Volume in Patients With Refractory Hypotension (Fresh-ER)

Sponsor
Ivor Douglas (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05101031
Collaborator
Oregon Health and Science University (Other), Baxter Healthcare Corporation (Industry)
50
1
24
2.1

Study Details

Study Description

Brief Summary

The objective of the study is to observe the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during rapid fluid bolus.

Condition or Disease Intervention/Treatment Phase
  • Device: Starling SV

Detailed Description

The Noninvasive Starling SV (Baxter Healthcare) is a portable, non-invasive, cardiac output detector system. The Starling SV system measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood.

The objective of the study is observe the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during the initial resuscitation of 30 ml/kg of fluid, to evaluate the feasibility of performing a larger prospective RCT of SV-guided resuscitation in patients who undergo a dynamic assessment of fluid responsiveness to help guide fluid administration.

This study is a prospective feasibility study. Patients will be evaluated by the Emergency Room team for Inclusion/Exclusion criteria. If the patient is found to fit the study inclusion and exclusion criteria, then the fully non-invasive Starling monitor will be applied to the patient and the patient's hemodynamic data will be prospectively collected during the initial fluid resuscitation.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Evaluation of Fluid Volume in Patients With Refractory Hypotension (Fresh-ER)
Actual Study Start Date :
Dec 18, 2020
Anticipated Primary Completion Date :
Dec 17, 2022
Anticipated Study Completion Date :
Dec 17, 2022

Arms and Interventions

Arm Intervention/Treatment
Denver Health Medical Center

SV machine will be attached if hypotensive and in the emergency department

Device: Starling SV
The Starling SV will monitor the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during the initial fluid resuscitation in individuals with hypotension related to infection.

Outcome Measures

Primary Outcome Measures

  1. Stroke Volume Change [During fluid bolus]

    Change in stroke volume following the administration of each 500 cc fluid bolus.

Secondary Outcome Measures

  1. Stroke Volume Difference [during fluid bolus]

    Concordance between change in stroke volume compared between fluid bolus and other usual care assessments of effective circulating volume

  2. Fluid Input and Output [72 hours]

    Fluid balance inclusive of all parenteral fluids and all output

  3. LOS in ICU [Up to 180 days from ICU admission]

    Length of ICU stay (days) until subject is medically ready for discharge

  4. Mechanical ventilation [28 days]

    Requirement for mechanical ventilation during hospitalization

  5. Vasopressor Use [28 days]

    Requirement for vasopressor use during hospitalization

  6. Serum Creatinine Levels [28 days]

    Changes in serum creatinine levels from baseline

  7. Renal Replacement Therapy [28 days]

    Requirement for renal replacement therapy (RRT)

  8. MACE [28 days]

    Incidence of Major Adverse Cardiac Event (MACE)

  9. Adverse Events [28 days]

    Incident of Adverse Events

  10. Mortality [28 days]

    Inhospital Mortality rate

  11. Discharge Location [Up to 180 days from hospital admission]

    Discharge location after hospitalization

  12. Fluid Input and Output in ICU [28 days]

    Mean difference in fluid balance at ICU discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Primary Criteria

  1. MAP <65

  2. SBP <90 or BP rapidly trending lower

Secondary Criteria

  1. Low urine output Acute change in urine output less than 50ml/4 hours

  2. Persistent hyperlactatemia

  3. A new vasopressor started

  4. Acute change in HR less than 50 or greater than 120

  5. New onset chest pain or chest pain different then admission assessment

  6. Acute bleeding

  7. Fever > 39 degrees

  8. Significant change in mental status: confusion, agitation, delirium, etc.

  9. Unexplained lethargy

  10. CRT >2 seconds -

Exclusion Criteria:
  1. Primary diagnosis of: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmatics, major cardiac arrhythmia, drug overdose, or injury from burn or trauma

  2. Known aortic insufficiency, or aortic abnormalities

  3. Requires immediate surgery

  4. Advanced directives restricting implementation of the resuscitation protocol

  5. Known intraventricular heart defect, such as VSD or ASD

  6. Prisoner

  7. Pregnancy

  8. Age <18

  9. Known allergy to sensor material or gel

  10. Suspected intra-abdominal hypertension

  11. Inability to obtain IV access

  12. Patient should be excluded based on the opinion of the Clinician/Investigator

  13. Patient has an unstable airway

Contacts and Locations

Locations

Site City State Country Postal Code
1 Denver Health Medical Center Denver Colorado United States 80204

Sponsors and Collaborators

  • Ivor Douglas
  • Oregon Health and Science University
  • Baxter Healthcare Corporation

Investigators

  • Principal Investigator: Ivor Douglas, MD, Denver Health Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ivor Douglas, Chief of Pulmonary and Medical Critical Care, Denver Health and Hospital Authority
ClinicalTrials.gov Identifier:
NCT05101031
Other Study ID Numbers:
  • 20-2845
First Posted:
Oct 29, 2021
Last Update Posted:
May 26, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Ivor Douglas, Chief of Pulmonary and Medical Critical Care, Denver Health and Hospital Authority
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 26, 2022